Latest Pharma Insights
China’s New Five-Year Plan Signals Shift To Quality And Innovation
China’s 15th five-year plan elevates healthtech to a strategic national priority and increases the weighting on innovation and quality. This will have implications for volume-based procurement, the wording around which has altered. L.E.K. Consulting explained the rationale.
Medtech Insight - August 9, 2026
China’s 15th five-year plan elevates healthtech to a strategic national priority and increases the weighting on innovation and quality. This will have implications for volume-based procurement, the wording around which has altered. L.E.K. Consulting explained the rationale.
Medtech Insight - August 9, 2026
Braveheart, Latigo, BlossomHill Perform Well In Public Market Debuts
Braveheart Bio, Latigo Biotherapeutics and BlossomHill Therapeutics raised a combined $935.5m and all three ended their first days of trading in positive territory.
Scrip - August 7, 2026
Braveheart Bio, Latigo Biotherapeutics and BlossomHill Therapeutics raised a combined $935.5m and all three ended their first days of trading in positive territory.
Scrip - August 7, 2026
Deal Watch: Tarsus Seeks Another Ophthalmology Buy With Alkeus Takeout Bid
Plus deals involving Arcturus/CSL, Harrow/Viatris, Evotec/Odyssey, Processa/Vidya, Scancell/Neuphoria as well as the latest technology transfer agreements.
Scrip - August 7, 2026
Plus deals involving Arcturus/CSL, Harrow/Viatris, Evotec/Odyssey, Processa/Vidya, Scancell/Neuphoria as well as the latest technology transfer agreements.
Scrip - August 7, 2026
SMID Cap Earnings In Brief: Sarepta, Arcturus, Iovance, BioMarin, Viridian & Roivant
Sarepta’s revenues fell as Michael Severino took the CEO role; Arcturus took back rights to its mRNA COVID-19 vaccine; Iovance and Viridian saw encouraging signs for their approved products; and Roivant is getting ready to launch brepocitinib.
Scrip - August 7, 2026
Sarepta’s revenues fell as Michael Severino took the CEO role; Arcturus took back rights to its mRNA COVID-19 vaccine; Iovance and Viridian saw encouraging signs for their approved products; and Roivant is getting ready to launch brepocitinib.
Scrip - August 7, 2026
IPF Pipeline’s Next Big Readout: Bristol’s Admilparant Pivotal Trial
In a disease with slow therapeutic progress, Boehringer Ingelheim’s Jascayd launch progress raises interest in Bristol Myers Squibb’s admilparant and other late-stage idiopathic pulmonary fibrosis candidates.
Scrip - August 7, 2026
In a disease with slow therapeutic progress, Boehringer Ingelheim’s Jascayd launch progress raises interest in Bristol Myers Squibb’s admilparant and other late-stage idiopathic pulmonary fibrosis candidates.
Scrip - August 7, 2026
Executives On The Move: Five CEOs And Six CMOs Among This Week’s Changes
Recent moves in the industry include changes at the top at Cyllene Therapeutics, Secretome Therapeutics and Ascentage Pharma, plus Kymera Therapeutics gets a new CMO from Johnson & Johnson.
Scrip - August 7, 2026
Recent moves in the industry include changes at the top at Cyllene Therapeutics, Secretome Therapeutics and Ascentage Pharma, plus Kymera Therapeutics gets a new CMO from Johnson & Johnson.
Scrip - August 7, 2026
Aurobindo Claims 5-7 Year Headstart With A1 Biochem, Lannett Acquisitions
The acquisition of US-based Lannett and India’s A1 Biochem, that has a US lab, have helped Aurobindo Pharma leapfrog onshoring and R&D capability scale-ups by five to seven years, giving it the confidence to handle mandatory US onshoring if required.
Scrip - August 7, 2026
The acquisition of US-based Lannett and India’s A1 Biochem, that has a US lab, have helped Aurobindo Pharma leapfrog onshoring and R&D capability scale-ups by five to seven years, giving it the confidence to handle mandatory US onshoring if required.
Scrip - August 7, 2026
Biocon Bullish On US Eylea Biosimilar, Says Regulatory Shift Sharpens Edge For Incumbents
Biocon expects to make the headstart for its Eylea biosimilar in the US count and indicates that its product pipeline stands to gain from recent regulatory streamlining.
Scrip - August 7, 2026
Biocon expects to make the headstart for its Eylea biosimilar in the US count and indicates that its product pipeline stands to gain from recent regulatory streamlining.
Scrip - August 7, 2026
China’s New Five-Year Plan Signals Shift To Quality And Innovation
China’s 15th five-year plan elevates healthtech to a strategic national priority and increases the weighting on innovation and quality. This will have implications for volume-based procurement, the wording around which has altered. L.E.K. Consulting explained the rationale.
Medtech Insight - August 9, 2026
China’s 15th five-year plan elevates healthtech to a strategic national priority and increases the weighting on innovation and quality. This will have implications for volume-based procurement, the wording around which has altered. L.E.K. Consulting explained the rationale.
Medtech Insight - August 9, 2026
Beiersdorf Accelerates Nivea Growth Plan With €100M Marketing Boost in 2H
Beiersdorf is accelerating its Nivea growth strategy in the next phase of its brand rebalancing strategy after the brand dragged Consumer Business sales down 4% organically to €4.1bn the first half of 2026.
HBW Insight - August 8, 2026
Beiersdorf is accelerating its Nivea growth strategy in the next phase of its brand rebalancing strategy after the brand dragged Consumer Business sales down 4% organically to €4.1bn the first half of 2026.
HBW Insight - August 8, 2026
Viatris Raises Outlook Despite $150m Manufacturing Hit
Viatris has raised its 2026 outlook despite a manufacturing disruption set to cost up to $150m in second-half sales, as stronger complex generics, transdermals and cost savings offset pressure from lower-margin products.
Generics Bulletin - August 7, 2026
Viatris has raised its 2026 outlook despite a manufacturing disruption set to cost up to $150m in second-half sales, as stronger complex generics, transdermals and cost savings offset pressure from lower-margin products.
Generics Bulletin - August 7, 2026
EU Urged To Reject ‘Industrially Unviable’ Export Restrictions
Medicines for Europe has urged the CJEU to reject limits on the SPC manufacturing waiver involving export storage, third-country marketing authorizations and foreign patent rights.
Generics Bulletin - August 7, 2026
Medicines for Europe has urged the CJEU to reject limits on the SPC manufacturing waiver involving export storage, third-country marketing authorizations and foreign patent rights.
Generics Bulletin - August 7, 2026
Diversification Gives Fresenius Kabi Room To Absorb Manufacturing Setbacks
Fresenius Kabi’s faster-growing businesses are overtaking its legacy pharma operations, helping offset fresh FDA scrutiny at Melrose Park as the firm’s Biopharma unit helps drive stronger financials.
Generics Bulletin - August 7, 2026
Fresenius Kabi’s faster-growing businesses are overtaking its legacy pharma operations, helping offset fresh FDA scrutiny at Melrose Park as the firm’s Biopharma unit helps drive stronger financials.
Generics Bulletin - August 7, 2026
Sonomind’s Mental Health Innovation Gets The Plaudits At French Medtech Start-Up Awards
France’s 11th annual medtech start-up awards in Paris yielded a standout winner in Sonomind, developer of mental health ultrasound, while BlueBack’s sensor-based real- time pelvic floor monitoring device took the CSR award.
In Vivo - August 7, 2026
France’s 11th annual medtech start-up awards in Paris yielded a standout winner in Sonomind, developer of mental health ultrasound, while BlueBack’s sensor-based real- time pelvic floor monitoring device took the CSR award.
In Vivo - August 7, 2026
Video Podcast - Proof of Concept: AI in Drug Discovery
Can AI and simulation make the earliest, riskiest decisions in drug discovery faster and more reliable?
In Vivo - August 7, 2026
Can AI and simulation make the earliest, riskiest decisions in drug discovery faster and more reliable?
In Vivo - August 7, 2026